Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$957.1 million.

  • Seres Therapeutics' Retained Earnings rose 56.04% to -$957.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$957.1 million, marking a year-over-year increase of 56.04%. This contributed to the annual value of -$978.1 million for FY2024, which is 1.39% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Retained Earnings is -$957.1 million, which was up 56.04% from -$965.3 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Retained Earnings peaked at -$564.4 million during Q3 2021, and registered a low of -$1.1 billion during Q2 2024.
  • In the last 5 years, Seres Therapeutics' Retained Earnings had a median value of -$935.7 million in 2023 and averaged -$846.3 million.
  • Per our database at Business Quant, Seres Therapeutics' Retained Earnings plummeted by 4099.6% in 2022 and then skyrocketed by 817.76% in 2025.
  • Quarter analysis of 5 years shows Seres Therapeutics' Retained Earnings stood at -$614.4 million in 2021, then tumbled by 40.72% to -$864.5 million in 2022, then dropped by 13.15% to -$978.2 million in 2023, then rose by 0.01% to -$978.1 million in 2024, then grew by 2.15% to -$957.1 million in 2025.
  • Its Retained Earnings stands at -$957.1 million for Q3 2025, versus -$965.3 million for Q2 2025 and -$945.4 million for Q1 2025.